Axim Biotechnologies Inc (AXIM) Return on Equity ROE from the second quarter 2024 to second quarter 2023 and annually, average high and low, overall ranking from Jun 30 2024 to Jun 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Axim Biotechnologies Inc   (AXIM)

Axim Biotechnologies Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Axim Biotechnologies Inc in the second quarter 2024?
Due to the lack of equity, it was not possible to calculate Axim Biotechnologies Inc 's return on equity (ROE) in its second quarter 2024

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -4 -6 -8 -7 -9
Return On Equity (TTM) - - - - -
AXIM's Total Ranking # # # # #
Equity (TTM) in Millions -10 -7 -8 -6 -10
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to AXIM Management Effectiveness >> AXIM's 5 Years Annual ROE >> Compare AXIM ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





AXIM Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019
Total Equity in Millions -8 -5 -2 2 -7
Y / Y Equity Change - - - - -
Net Income in Millions -8 -6 -16 -6 -6
Y / Y Net Income Change - - - - -
Return On Equity - - - -409.36 % -

Back to AXIM Management Effectiveness >> AXIM's 5 Years Annual ROE >> Compare AXIM ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
AXIM's' Return on Equity at Yahoo Finance
AXIM's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for AXIM's Competitors
Subscribers only: Roe for Axim Biotechnologies Inc 's Suppliers
Subscribers only: Return On Equity for AXIM's Customers




Companies with similar Return On Equity at Jun 30 2024, within Healthcare Sector ROE
Viskase Holdings inc   118.96 %
Davita Inc   99.50 %
Roivant Sciences Ltd   91.17 %
Tenet Healthcare Corp  88.36 %
Mimedx Group Inc   86.80 %
Earth Science Tech Inc   82.87 %
Cardiff Lexington Corporation  82.47 %
Guardion Health Sciences Inc   77.24 %
Dariohealth Corp   74.64 %
Nrc Health  63.64 %
Entrada Therapeutics Inc   62.08 %
Eli Lilly And Company  60.30 %
Abbvie Inc   57.23 %
Idexx Laboratories Inc  57.03 %
Medpace Holdings Inc   55.14 %
Johnson and Johnson  54.01 %
Siga Technologies Inc  51.39 %
Pharmacyte Biotech Inc   51.37 %
Insulet Corporation  50.53 %
Waters Corporation  50.44 %
Amgen Inc   50.41 %
Entera Bio Ltd   49.93 %
Lantheus Holdings Inc   49.15 %
Collegium Pharmaceutical Inc   49.14 %
Carlisle Companies Incorporated  47.37 %
Zoetis Inc   46.66 %
Scienture Holdings Inc   45.02 %
Precision Biosciences Inc  42.46 %
Elite Pharmaceuticals Inc   41.25 %
Protagonist Therapeutics inc   39.06 %

Date modified: 2026-09-08T15:11:18+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.